肠外与肠内营养
腸外與腸內營養
장외여장내영양
PARENTERAL & ENTERAL NUTRITION
2010年
2期
98-100,105
,共4页
癌症恶病质%福莫特罗%吲哚美辛%罗红霉素%联合治疗
癌癥噁病質%福莫特囉%吲哚美辛%囉紅黴素%聯閤治療
암증악병질%복막특라%신타미신%라홍매소%연합치료
Cancer cachexia%Formoterol%Indomethacin%Roxithromycin%Combination therapy
目的: 研究福莫特罗、吲哚美辛和罗红霉素对癌症恶病质小鼠的联合治疗作用,并探讨其可能机制. 方法: 将小鼠结肠腺癌Colon26 (C26)细胞接种于雄性Babl/c小鼠皮下后9 d,建立癌症恶病质模型.随机分为九组:A组(正常对照组)、B组(生理盐水治疗组)、C组(福莫特罗治疗组)、D组(吲哚美辛治疗组)、E组(罗红霉素治疗组)、F组(福莫特罗+吲哚美辛治疗组)、G组(福莫特罗+罗红霉素治疗组)、H组(吲哚美辛+罗红霉素治疗组)、I组(福莫特罗+吲哚美辛+罗红霉素治疗组).观察癌症恶病质小鼠治疗后的体质量、去瘤体质量、食物摄入量、左侧腓肠肌重量和血清清蛋白、血糖、三酰甘油、TNF-α、IL-6水平. 结果: 荷瘤小鼠去瘤体质量明显下降,清蛋白和血糖水平明显降低,三酰甘油、TNF-α、IL-6水平升高.三药联合治疗组与其他组相比,左侧腓肠肌重量增加,血糖升高,三酰甘油降低,血清TNF-α降低. 结论: 福莫特罗、吲哚美辛和罗红霉素在一定程度上均具有抗癌症恶病质的作用,三药联合治疗恶病质效果更好.
目的: 研究福莫特囉、吲哚美辛和囉紅黴素對癌癥噁病質小鼠的聯閤治療作用,併探討其可能機製. 方法: 將小鼠結腸腺癌Colon26 (C26)細胞接種于雄性Babl/c小鼠皮下後9 d,建立癌癥噁病質模型.隨機分為九組:A組(正常對照組)、B組(生理鹽水治療組)、C組(福莫特囉治療組)、D組(吲哚美辛治療組)、E組(囉紅黴素治療組)、F組(福莫特囉+吲哚美辛治療組)、G組(福莫特囉+囉紅黴素治療組)、H組(吲哚美辛+囉紅黴素治療組)、I組(福莫特囉+吲哚美辛+囉紅黴素治療組).觀察癌癥噁病質小鼠治療後的體質量、去瘤體質量、食物攝入量、左側腓腸肌重量和血清清蛋白、血糖、三酰甘油、TNF-α、IL-6水平. 結果: 荷瘤小鼠去瘤體質量明顯下降,清蛋白和血糖水平明顯降低,三酰甘油、TNF-α、IL-6水平升高.三藥聯閤治療組與其他組相比,左側腓腸肌重量增加,血糖升高,三酰甘油降低,血清TNF-α降低. 結論: 福莫特囉、吲哚美辛和囉紅黴素在一定程度上均具有抗癌癥噁病質的作用,三藥聯閤治療噁病質效果更好.
목적: 연구복막특라、신타미신화라홍매소대암증악병질소서적연합치료작용,병탐토기가능궤제. 방법: 장소서결장선암Colon26 (C26)세포접충우웅성Babl/c소서피하후9 d,건립암증악병질모형.수궤분위구조:A조(정상대조조)、B조(생리염수치료조)、C조(복막특라치료조)、D조(신타미신치료조)、E조(라홍매소치료조)、F조(복막특라+신타미신치료조)、G조(복막특라+라홍매소치료조)、H조(신타미신+라홍매소치료조)、I조(복막특라+신타미신+라홍매소치료조).관찰암증악병질소서치료후적체질량、거류체질량、식물섭입량、좌측비장기중량화혈청청단백、혈당、삼선감유、TNF-α、IL-6수평. 결과: 하류소서거류체질량명현하강,청단백화혈당수평명현강저,삼선감유、TNF-α、IL-6수평승고.삼약연합치료조여기타조상비,좌측비장기중량증가,혈당승고,삼선감유강저,혈청TNF-α강저. 결론: 복막특라、신타미신화라홍매소재일정정도상균구유항암증악병질적작용,삼약연합치료악병질효과경호.
Objective: To observe the effect of the combinative supplementation of Formoterol, Indomethacin and Roxithromycin on cancer cachexia (CC) and to study the mechanism. Methods: Male BALB/c mice bearing colon 26 adenocarcinoma for 9 days were served as models of cancer cachexia. The mice were divided into nine groups. Physiological conditions, body weight and food intake were documented every day. Serum levels of cytokine and nutritional markers were detected 7 days after treatment. Results: Tumor-bearing caused a wasting of non-tumor body weight and gastrocnemius muscle. Serum tumor necrosis factor-α, (TNF-α) and interleukin-6 (IL-6) levels were significantly elevated accompanied with nutrition depletion in tumor-bearing mice. After treatment with combinative supplementation of Formoterol, Indomethacin and Roxithromycin, left gastrocnemius weight and serum glucose were improved and the levels of TNF-α and triglyceride were down-regulated. Conclusion: Formoterol, Indomethacin and Roxithromycin had their own positive effects to CC mice. Drugs combinationin in tumor-bearing mice with cancer cachexia could produce synergistic action.
